Your browser doesn't support javascript.
Neutralizing Antibody Responses in COVID-19 Convalescent Sera.
Lee, William T; Girardin, Roxanne C; Dupuis, Alan P; Kulas, Karen E; Payne, Anne F; Wong, Susan J; Arinsburg, Suzanne; Nguyen, Freddy T; Mendu, Damodara Rao; Firpo-Betancourt, Adolfo; Jhang, Jeffrey; Wajnberg, Ania; Krammer, Florian; Cordon-Cardo, Carlos; Amler, Sherlita; Montecalvo, Marisa; Hutton, Brad; Taylor, Jill; McDonough, Kathleen A.
  • Lee WT; Wadsworth Center, New York State Department of Health, Albany, New York, USA.
  • Girardin RC; Department of Biomedical Sciences, School of Public Health, State University of New York at Albany, Albany, New York, USA.
  • Dupuis AP; Wadsworth Center, New York State Department of Health, Albany, New York, USA.
  • Kulas KE; Wadsworth Center, New York State Department of Health, Albany, New York, USA.
  • Payne AF; Wadsworth Center, New York State Department of Health, Albany, New York, USA.
  • Wong SJ; Wadsworth Center, New York State Department of Health, Albany, New York, USA.
  • Arinsburg S; Wadsworth Center, New York State Department of Health, Albany, New York, USA.
  • Nguyen FT; Department of Pathology, Molecular, and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • Mendu DR; Department of Pathology, Molecular, and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • Firpo-Betancourt A; Department of Pathology, Molecular, and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • Jhang J; Department of Pathology, Molecular, and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • Wajnberg A; Department of Pathology, Molecular, and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • Krammer F; Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • Cordon-Cardo C; Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • Amler S; Department of Pathology, Molecular, and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • Montecalvo M; Westchester County Department of Health, White Plains, New York, USA.
  • Hutton B; Westchester County Department of Health, White Plains, New York, USA.
  • Taylor J; New York State Department of Health, Albany, New York, USA.
  • McDonough KA; Wadsworth Center, New York State Department of Health, Albany, New York, USA.
J Infect Dis ; 223(1): 47-55, 2021 01 04.
Article in English | MEDLINE | ID: covidwho-889569
Preprint
This scientific journal article is probably based on a previously available preprint. It has been identified through a machine matching algorithm, human confirmation is still pending.
See preprint
ABSTRACT
Passive transfer of antibodies from COVID-19 convalescent patients is being used as an experimental treatment for eligible patients with SARS-CoV-2 infections. The United States Food and Drug Administration's (FDA) guidelines for convalescent plasma initially recommended target antibody titers of 160. We evaluated SARS-CoV-2 neutralizing antibodies in sera from recovered COVID-19 patients using plaque reduction neutralization tests (PRNT) at moderate (PRNT50) and high (PRNT90) stringency thresholds. We found that neutralizing activity significantly increased with time post symptom onset (PSO), reaching a peak at 31-35 days PSO. At this point, the number of sera having neutralizing titers of at least 160 was approximately 93% (PRNT50) and approximately 54% (PRNT90). Sera with high SARS-CoV-2 antibody levels (>960 enzyme-linked immunosorbent assay titers) showed maximal activity, but not all high-titer sera contained neutralizing antibody at FDA recommended levels, particularly at high stringency. These results underscore the value of serum characterization for neutralization activity.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Neutralization Tests / Antibodies, Neutralizing / COVID-19 / Antibodies, Viral Type of study: Experimental Studies Limits: Humans Language: English Journal: J Infect Dis Year: 2021 Document Type: Article Affiliation country: Infdis

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Neutralization Tests / Antibodies, Neutralizing / COVID-19 / Antibodies, Viral Type of study: Experimental Studies Limits: Humans Language: English Journal: J Infect Dis Year: 2021 Document Type: Article Affiliation country: Infdis